Back
Dermata Therapeutics 10K Form
Sell
20
DRMA
Dermata Therapeutics
Last Price:
1.16
Seasonality Move:
-57.39%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive DRMA News And Ratings
See the #1 stock for the next 7 days that we like better than DRMA
DRMA Financial Statistics
Sales & Book Value
Annual Sales: | -- |
---|---|
Cash Flow: | $-2.13M |
Price / Cash Flow: | 0 |
Annual Sales: | $4.79 |
Price / Book: | 0.49 |
Profitability
EPS (TTM): | -27.47320 |
---|---|
Net Income (TTM): | $-9.82M |
Gross Margin: | -- |
Return on Equity: | 0% |
Return on Assets: | 0% |
Dermata Therapeutics Earnings Forecast
Key Dermata Therapeutics Financial Ratios
- The Interest Expense is 0.62% of Operating Income.
- Per Share Earnings over the last 5 years have been positive in 3 years.
Dermata Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | DRMA |
Website: | dermatarx.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 0 |
Quick Ratio: | 0 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
DRMA Technical Analysis vs Fundamental Analysis
Sell
20
Dermata Therapeutics (DRMA)
is a Sell
Is Dermata Therapeutics a Buy or a Sell?
-
Dermata Therapeutics stock is rated a Sell
The current Dermata Therapeutics [DRMA] share price is $1.23. The Score for DRMA is 20, which is 60% below its historic median score of 50, and infers higher risk than normal.